imipramine, Tofranil, Tofranil-PM (cont.)Pharmacy Author:
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmDDr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99. Medical and Pharmacy Editor:
Jay W. Marks, MD
Jay W. Marks, MDJay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles. Serious side effects include high blood pressure, low blood pressure when standing (orthostatic hypotension), fainting, heart attack, stroke, seizures, hepatitis, and abnormal heart beats (arrhythmia). Imipramine also can cause elevated pressure in the eyes of some patients with glaucoma. Following prolonged therapy with high doses, abrupt discontinuation of TCAs, including imipramine, could lead to withdrawal symptoms such as nausea, vomiting, diarrhea, or restlessness. Therefore, many experts recommend gradually reducing the dose of drug if the drug is to be discontinued. Antidepressants increased the risk of suicidal thinking and behavior in short-term studies in children and adolescents with depression and other psychiatric disorders. Anyone considering the use of imipramine or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be closely observed for clinical worsening, suicidal thinking or behavior, and unusual changes in behavior. Reference: FDA Prescribing Information Last Editorial Review: 2/2/2012
Back to Medications Index |
Get the latest health and medical information delivered direct to your inbox FREE!


